ArticleFrontiers in pharmacology2021

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study.

D J Ouyang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.